The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Great update from CEO this morning. He is obviously certain of delivering the quality LFD we are waiting for and that is so needed. It's obviously all on track and we are only days away from the RNS.
He is consistent, professional and keeps delivering. I couldn't resist a little top up today at these prices. I can't believe some are selling particularly with this update.
GLA
Continued:
Tim Cornelius, CEO of SIMEC Atlantis Energy, commented:
"The successful completion of the fuel combustion testing is a major milestone for this flagship conversion project and represents a very important step in the program towards achieving financial close.
This project is the world's first example of a coal-fired power station being repurposed to run on 100% waste derived fuel pellets and the results of this test will potentially have material implications for the way plastic waste, and aging coal fired power stations, is managed globally in the future."
Falk Hoffmeister, Vice President Head of Service of Mitsubishi Hitachi Power Systems Europe, commented:
"We were delighted to work with Atlantis on the combustion testing for the flagship Uskmouth project and we always believed that the successful completion of this large-scale testing will open up a huge new market globally for MHPS and Atlantis for future similar conversions. The testing couldn't have gone better and we are delighted that the results pave the way for this successful project and huge global, future opportunities."
Lars Jennissen, Chief Development Officer of N+P Group B.V. commented:
"After two years of development we are delighted with the achieved results, a major milestone for everyone involved in the project. The bespoke pellet, especially designed for the demanding environment of a pulverized fuel furnace, performed very well in the trials. This result gives us as a company a lot of confidence that the flagship Uskmouth project will prove to the world that coal fired power plants can be converted to use bespoke waste derived fuels and in this way contribute to reducing non-recyclable waste going to landfills as well as contributing to a significant CO2 reduction for power generation."
SIMEC ATLANTIS ENERGY LIMITED
("Atlantis", the "Company" or the "Group")
Successful fuel tests represent significant milestone
for Uskmouth Power Station Conversion Project ("Uskmouth Conversion Project")
SIMEC Atlantis Energy, the global developer, owner and operator of sustainable energy projects, announces the successful completion of industrial-scale combustion testing of the waste derived fuel pellets to be used at the Uskmouth Conversion Project.
In October 2019, Atlantis announced that it had awarded Mitsubishi Hitachi Power Systems Europe GmbH ("MHPS") the contract to carry out the design and development of the combustion system for the flagship Uskmouth Conversion Project. This contract included the largest ever combustion testing of the fuel pellets, which will be used as fuel in the Uskmouth Conversion Project, at Mitsubishi Heavy Industries's Research & Innovation Centre in Nagasaki (Japan).
Successful completion of this testing is a significant milestone for the project. The test conclusively proves that a pulverised fuel burner based on MHPS's DS® Ultra Low NOx burner can be used to stably combust the waste derived fuel unsupported (i.e. without any oil or gas support firing). The burner was able to operate continuously at 25MW thermal power using the fuel and is comparable in rating to the burners required for the Uskmouth Conversion Project.
During the testing MHPS established that it was possible to feed large volumes of pulverised fuel to the burner via a pneumatic system without disturbances, at a rate that is comparable to that required at the Uskmouth Conversion Project. MHPS also investigated and confirmed that flue gas emissions were within anticipated levels and that the burner was able to achieve expected low NOx performance whilst maintaining low CO levels.
Following successful completion of the test the final stages of the pre-EPC detailed design contract is now underway. Final design studies include using the successful combustion test results to validate the computational fluid dynamics modelling, carrying out more detailed Uskmouth boiler system refurbishment design and confirming the requirements for refurbishment and enhancement of the existing flue gas treatment system. MHPS will have completed all of this work by Q4 2020 at which point they will be able to make an offer for a fixed price supply of the combustion system under an EPC contract with terms and conditions suitable for project finance.
The bespoke fuel pellets, designed and produced by project partner and leading Dutch alternative fuel specialist N+P Group, contain approximately 50% biogenic waste material (such as paper and cardboard), with the remainder made up predominantly of plastic waste. The waste used to make the pellets is not currently economically recyclable and therefore, if not used in production of fuel pellets, would be sent to landfill or diverted from landfill to purpose-bu
This is not normal. Being restricted from seeing friends, family, going on holidays, watching live sport.
Hundreds of thousands losing jobs and businesses going into administration. We are just starting to see the economic effects of this.
The testing isn't just about saving lives it's about saving the economy.
The mention in the press releases of Avacta has to be positive, its further confirmation of Alistair Smith's previous statement that the uk Government are aware of Avacta's work and another demonstration of work going on behind the scenes. This could well be with reference to the BAMS testing or both the LFD and the BAMS we will have to wait and see. Exciting times.
GLA
Great positive news.
GLA
Whilst we all try see into the future and predict the Market, we will just have to wait. What we do know is we have news coming, if the news is positive regards to the quality of the LFD the share price will fly.
We know that, Avacta's CEO stated in the latest RNS on the 18.6.20, “We continue to make very good progress across all of our COVID-19 related programmes, as well as our other diagnostic and therapeutic activities, and I look forward to providing further updates in the very near future."
We also know we have the following news flows coming:
22.6.20 Avacta’s AGM
RNS expected by the end of the month providing updates on production of prototype LFD. With further RNS updates on the testing and manufacturing of the LFD over the next month.
25.6.20 the release of the additional shares. Which will help to hold down share price if they are sold for a quick profit.
RNS update on the evaluation of the BAMS diagnostic prototype test. Last RNS on the prototype was on the 9.6.20.
RNS update on a partnership with a large pharmaceutical company to develop an Affimer reagent therapy treatment for Covid 19.
RNS updates regarding manufacturing and sales of LFD and BAMS.
All makes for very exciting few weeks with news potential on numerous fronts which have the potential to raise the share price above the previous recent high of £2.10.
I am sure we will get the wave of derampers coming in to try and manipulate the share price, but its useful to focus on the above news flow items which have all come Avacta and their CEO. My view is that the focus should be on investing and holding for months and years in Avacta, however I am hopeful that we get some positive news soon to steady the nerves and subdue the derampers.
GLA.
My aim is to take some profit out to cover my original investment. That will hopefully be in the £4-£5 on the back of Covid developments.
But I intend to hold the majority of my investment until the development and role out of the cancer treatment.
But with this Affimer technology and possibilities of partnerships with large pharmaceutical or takeovers I want to be still invested longer term.
Hopefully we will be near that first target at the end of summer.
GLA
Brightspark,
Could it be because of the development, production and clinical validation of a LFD made by a british company, that will transform the testing for Covid 19.
Don't tell anyone else yet, but I'll give you a clue:
_ VACT_
Do people think the anticipated RNS update on the LFD will confirm that they have already carried out clinical validation? If not how long would that process be?
Cheers
Avacta's CEO stated in the latest RNS on the 18.6.20, “We continue to make very good progress across all of our COVID-19 related programmes, as well as our other diagnostic and therapeutic activities, and I look forward to providing further updates in the very near future."
I have been trying to clarify what news flow we can expect in the next few weeks which could have a big affect on the share price:
22.6.20 Avacta’s AGM may get further clarity on progress, probably not much information on news flow items, unless in an RNS before the meeting.
RNS expected by the end of the month providing updates on production of prototype LFD. With further RNS updates on the testing and manufacturing of the LFD over the next month.
25.6.20 the release of the additional shares. Which will help to hold down share price if they are sold for a quick profit.
RNS update on the evaluation of the BAMS diagnostic prototype test. Last RNS on the prototype was on the 9.6.20.
RNS update on a partnership with a large pharmaceutical company to develop an Affimer reagent therapy treatment for Covid 19.
RNS updates regarding manufacturing and sales of LFD and BAMS.
All makes for very exciting few weeks with news potential on numerous fronts which have the potential to raise the share price above the previous recent high of £2.10.
I am sure we will get the wave of derampers coming in to try and manipulate the share price, but its useful to focus on the above news flow items which have all come Avacta and their CEO.
GLA.
Great news this morning and just as the derampers were probably planning another assault to cause panic. This RNS again further demonstrates the affimer technology and multiply benefits that Avacta holds over others.
The desire to get this to market with large pharmaceutical company can surely benefit the Cancer treatment therapies if and when Affimers are used in humans to treat covid.
The real thing I learnt from the last night's webinar was how complex these treatments and tests are and the need to get it right. We need to have patience and get it right for the long term benefit of Avacta, patients and shareholders.
Last night I was reasured that Avacta are supremely confident they are going to deliver the covid tests.
Alistair Smith is a straight talking Yorkshireman, all he states is happening. We really need to understand how difficult these challenges are, how many balls they are now juggling. We need some patience, to maintain our confidence and really listen to what he says and not the posters clamering constant news. I invested in Avacta because of my confidence in the CEO, the regular communication and the long term opportunities. GLA
Update on Affimer® Therapy for COVID-19 Infection
Infectivity assays carried out in collaboration with Glasgow University show that Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection.
Recently, Avacta reported that several of the Affimer reagents that had been generated to develop COVID-19 antigen tests inhibited the interaction between the coronavirus' spike protein and a receptor found on human cells, called ACE2, which the virus spike protein binds to as the first step in infecting cells.
Avacta has now successfully completed the initial phase of a collaboration with Professor David Bhella at the University of Glasgow showing that these "neutralising" Affimer reagents prevent a SARS-COV-2 model virus from entering human cells and therefore provide a potential therapy for COVID-19.
Affimer reagents have key benefits compared with antibodies as virus neutralising therapies: Their small size and high solubility means that a much higher concentration of Affimer molecules can be used in the drug formulation to more effectively block the spike proteins on each virus particle and better protect the patient; bispecific and trispecific Affimer neutralising therapies that bind to more than one part of the spike protein could ensure the effectiveness of the neutralising therapy even if the virus' spike protein mutates.
Work is continuing with Professor Bhella to further study the way in which the Affimer reagents prevent infection and Avacta is using this growing body of data actively to secure a large pharmaceutical partner to develop these potential therapeutic candidates rapidly.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"I am delighted that our collaborators at the University of Glasgow have confirmed that these Affimer reagents not only block the spike-ACE2 binding but efficiently prevent a SARS-COV-2 model virus from entering human cells. This is critical information that will help to establish a license deal with a large pharmaceutical partner that has the resources to carry out an accelerated clinical development programme.
Neutralising therapies could be given to those exposed to the virus, such as health and social-care workers, to prevent infection, as well as to patients already infected by the virus, to help treat and prevent disease progression. There is ongoing significant investment by large pharmaceutical companies such as AstraZeneca, GSK, Boehringer Ingelheim and others to develop neutralising therapies for COVID-19.
The webinar was informative and should have improved awareness of the challenges of bringing this test to market. It was very much initially focused on the challenges to overcome and the quality of the test required to be effective in testing.
My view was that a number of useful bits came out in the session in that these tests are going to be needed for some time in very large quantities and that there is a need to provide this LFD. The test is going to need to be above 95% to provide the necessary quality of test required and that Avacta are confident that this will be produced. GLA I am confident the wait will be worth it.
David Wilson has just stated how confident they are that this test will be brought to market. Nice to hear.
Great find.
I particularly like the statement from Alistair Smith, "This will keep us on track for launch of a product for professional use in the summer. A COVID-19 BAMS assay could provide highly sensitive and specific testing for up to a thousand samples per day in the hospital setting using standard equipment that is available but not currently used for coronavirus testing thus contributing significantly to an increase in global testing capacity. We continue to make very good progress with Cytiva on the saliva-based antigen test and I look forward to updating the market soon on both of these product developments as well as future additional partnerships.”
GLA wont be long now to news
The government have focused on soundbites with their messaging strategy.
Stay home
Protest the NHS
Save lives
I thought that Avacta should now take a leaf out of their book and prepare for the LFD launch. My initial thoughts are:
Get Avacta LFD for quick acurrate results
Easy test with no pain
Profits from purchase will help us treat cancer
Great for the NHS
Will save lives
Probably needs a bit of work but it's clear to me and that's why I have a tight grip of my holding. Just wish I had cash not tied up to get more.
GLA
Going to reset today after yesterday. Bigger buys starting to come in.
Jun 16 2020, 08:39 107.00 25,000 106.00 107.00 Buy £26,750.0000
Most importantly though a day closer to news.
GLA
I agree with many of the comments regarding the number one priority is to ensure we get the right product, secondary is the timescales. However Alistair has seen the reaction the last week, over the couple of weeks delay and seemed a bit frustrated with questions on the webinar about the speed of getting the LFD to market. I for one do not understand how difficult it is., he has explained it normal takes months or years to bring something like this to market and trying to deliver in weeks is some challenge. However I think he will have built abit of wriggle room into the end of of June statement, as he will want to maintain confidence. I would not be surprised to get an RNS on the prototype before the end of the month, which could very much catch some shareholders out. As we are getting closer to the news, its risky to not be holding, you could very much miss out. On a big climb.
We have got some very big players involved that are investing heavily and I'm sure they have had reassurance that Avacta can deliver the quality product.
We are in for a very exciting few months.
Dear tkevin,
I find myself constantly disappointed with modern society and individuals desire to attack others remotley particularly when they are working to help others. I like to think you would not go up to Alistair Smith and say the things your posting as it's not polite or accurate. Avacta's CEO is looking using Affimer technology to help with Covid19 and Cancer treatments. Why would you feel it appropriate to come attack his company and ability to do that, I can only thing to deramp the share. I have invested because I believe he can deliver some if not all he is striving to achieve.
I guess you are invested in another pharmaceutical hence your appearance on here. I wish your company success as I should it will help people if successful and I'm sure there is enough room I the industry for us all. I know you probably wont want some advice from me, but I'm going to give it anyway.
Try to be nice
Focus on positives
Think about others
I'm sure you have advice for me, but unfortunately I have filtered you so will not be able to see it. Good luck in the future .
Regards
The Cytiva webinar on the 17th June includes Sona as well as Avacta. They state that, this session will discuss the design challenges encountered during COVID-19 rapid point of care (POC) diagnostic test development, and the solutions that exist to overcome them.
Learning Objectives:
1. Understand current COVID-19 diagnostic technologies
2. Why a dual approach of both RT-PCR and lateral flow based tests is needed
3. Design challenges you need to be aware of when developing a COVID-19 lateral flow test
4. What support exists to help developers overcome design challenges
I cannot believe Cytiva or Avacta would have this event if all was not on track and have a positive story to tell. It would be difficult to discuss the LFD if they were having problems and have not found a solution, surely they would not hold a webinar. I am therefore hopefully we will get a positive RNS prior to the event. Are others of the same opinion?
Fingers crossed for an nice early RNS and a less stressful week.